Epitalon research: studies, doses and safety
A peptide with telomerase effects in cells, but no proof that people live longer.
Also called: Epithalon, Epithalone, AEDG, Ala-Glu-Asp-Gly.
Khavinson bioregulator peptides · Synthetic pineal tetrapeptide studied in telomere and circadian models.
A small night-shift-worker study used a sublingual Epitalon spray twice daily for 20 days; it measured body-clock gene activity.
Four human reports cover about three participant groups. Two night-shift reports likely reuse participants; longer human life is unproven.
Key studies
- Retinitis pigmentosa: local eye injections: An old controlled report suggests visual changes but lacks modern trial safeguards. (source)
- Older adults: 10 mcg IM course: A tiny IM study changed melatonin levels without showing better sleep or longer life. (source)
- Night-shift workers: sublingual spray: A small biomarker trial does not establish insomnia treatment. (source)
- Night-shift workers: companion gene report: A related report shows gene-expression changes after sublingual exposure. (source)
- Telomerase in human fibroblasts: The central telomerase claim began as a cell-culture finding. (source)
- Cultured cells beyond division limit: A culture result cannot establish human longevity. (source)
Related to Epitalon
- Pinealon: A peptide with unproven brain benefits and no established injection dose.
- Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
- Thymogen: A Russian peptide used for immune problems, with negative cancer trials.
- Vesugen: An experimental blood-vessel peptide with unclear benefits and poorly defined safety.
- Cortagen: A four-amino-acid brain peptide backed mainly by animal work and unverified patent claims.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- GenoGenix LLC - 718739 - 01/20/2026, FDA · FDA · 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), FDA · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- Risks of buying peptide products online, Therapeutic Goods Administration · 2026
- Sepsis, NHS · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Anaphylaxis, NHS · NHS · 2023
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.